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colonization begins immediately upon birth. While adults
have a gut microbiome that is quite robust and stable over
time, new-borns experience a dynamic microbial coloniza-
tion resulting in higher vulnerability and sensitivity to
disturbances. The new-born’s microbiome composition is
highly dependent on delivery mode (vaginal vs. caesarean)
and feeding choices (breastfeeding vs. formula), which may
directly impact child’s health by modulating risks for devel-
oping diseases like asthma or allergy. Breast milk is now
understood to be an additional source of microbes from the
mother towards the infant, and intriguingly, latest research
tells that the uterus is not completely sterile, although
whether it contributes to colonization prior to birth is highly
controversial. In particular, the role of labour or lack thereof,
remains enigmatic. This presentation will provide an over-
view of the different transmission routes and highlight
research on different cohorts of mother-infant pairs accord-
ing to different delivery modes. While many questions
remain to be addressed, new insights from the scientific field
may lead to new research opportunities for developing
strategies that mitigate the negative effects from deviations
in the early-life microbial colonization.
MODE OF DELIVERY, ROUTE OF DELIVERY AND
DIET ALL REGULATE INFANT MICROBIOTA AND
METABOLOME
Kieran M. Tuohy. Fondazione Edmund Mach, Italy
The intestinal microbiome is now recognised as playing an
important role in human health and disease, impacting on
many host physiological processes from metabolism and
immune homeostasis to brain development and even cogni-
tive function. Importantly, many of these physiological
processes appear to be affected by early life events. Maternal
health during pregnancy, term of birth, mode of delivery
(Spontaneous Vaginally Delivered or Caesarean-section),
infant diet (breast feeding, infant formula feed, fortified
infant formula) and exposure to microorganisms (both patho-
genic and commensal) all impact on neonatal physiological
development and later life health or disease risk. Many
studies, using different microbiological approaches have
characterised the successional development of the infant
gut microbiota. Some have also correlated microbiota com-
position with concomitant changes in health status (e.g.
incidence of infections) or physiological biomarkers. Studies
in animals and using in vitro microbiota models have ident-
ified prebiotics capable of modulating the architecture of the
infant gut microbiota and intervention studies in healthy
infants have also confirmed that infant formula fortified with
prebiotics can modulate the gut microbiota of formula fed
infants towards that of breast-fed infants. In this presentation
we will assess the potential of fructans (inulin and oligo-
fructuse in particular) as prebiotic ingredients capable of
modulating the composition of the infant gut microbiota. We
will discuss evidence of safety, tolerability and impact on
microbiota metabolic output. Finally, we will discuss the
need for wider application of whole systems metabolic
profiling or metabolomics to study the metabolic con-
sequences of microbiota modulation, using a specific
example data-set. In a collaborative study with University
College Cork in Ireland, we have measured the metabolic
implications of early life events in terms of urinary metab-
olite profiles using LC-MS based metabolomics in 199 breast
fed infants. Mode of delivery and term v pre-term birth
clearly impacted on urinary metabolite profiles, with 5000
statistically significant biomarkers separating infant groups.
Remarkably, these shifts in metabolite profiles reflected
closely differentiative clustering of faecal microbiota at
the same time point, indicating that gut microbiota derived
metabolites contribute significantly to the urinary metabo-
lome in infants and more importantly, that changes within
the intestinal microbiome brought on by early life events
have clear and measurable consequences in terms of infant
metabolism. These observations identify metabolomics as a
powerfully informative tool for studying diet:microbiota
interactions, especially in infants, and a technology likely
to provide new mechanistic insight linking microbiota
modulation with physiological response or health effects
in babies.
QUALITY OF PROBIOTIC PRODUCTS: WHAT IS
NEEDED?
H. Szajewska. The Medical University of Warsaw,
Department of Paediatrics, Warsaw, Poland
Many clinicians have concerns regarding the reliability of
some of the products currently on the market. Indeed, a
number of studies have questioned the microbiological
quality and labeling of many commercial probiotic products.
Only some of them met the definition of probiotics, i.e.,
contain viable, well-defined microorganisms in sufficient
numbers. A substantial percentage of products contained
other species of organisms. Products sold for medicinal
purposes tend to be of better quality than probiotics used
in dairy foods or probiotic supplements. This may be due to
the fact that in most countries, probiotics are not regulated as
drugs but are marketed as dietary supplements. This means
that they are not standardized. However, even top quality
probiotic products may suffer from some degree of product
variability. Probiotics are live microorganisms that survive in
the anaerobic environment. Factors such as oxygen, tempera-
ture, and humidity may have an impact on the maintaining
the viability of the probiotic strains at sufficiently high levels
to ensure their therapeutic activity throughout their shelf life.
Additionally, variations in manufacturing processes, quality
between batches, and packaging material may have an
impact on the final products. Accurate labeling is essential
for proper use of probiotics. Healthcare professionals and
consumers should be aware of possible variations. Until
issues are regulated, the only sound approach seems to be
to choose probiotic products from a recognized manufacturer
who has a regulated quality control of factors including the
composition and content of the probiotic bacteria and
adheres to good manufacturing practice.
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